StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Calquence (acalabrutinib) by Quarter

Calquence (acalabrutinib) — Worldwide product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Calquence (acalabrutinib): $1,022M in Q2 2026, up 17.2% from a year earlier. That is the highest of the 35 quarters on record here.

Latest, Q2 2026
1,022
Period ended Jun 30, 2026
Change on a year earlier
+17.2%
872 in Q2 2025
History
35 quarters
Since Q4 2017
Sources
27
Documents cited below

Where the Q2 2026 figure comes from

“|| Calquence | | 1,022 | | 17 | | 16 | | 687 | | 18 | | 67 | | 36 | | 30 | | 225 | | 13 | | 9 | | 43 | | 3 | | 3”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCalquence (acalabrutinib) — Worldwide product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20261,022+17.2%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026923+21.1%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025967+19.7%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025916+12.7%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025872+10.4%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025762+6.1%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024808+19.7%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024813+24.3%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024790+21.0%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024718+35.0%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023675+14.8%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023654+15.5%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023653+33.5%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023532+28.5%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022588+48.9%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022566+59.9%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up calquence (acalabrutinib)

Cite this data

StockData. (2026). AstraZeneca Calquence (acalabrutinib) ($M), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-calquence-world

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.